A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.
Sorafenib has been studied across 16 research domains including 🔬 Oncology, 🫁 Liver & Detox, ⏳ Longevity & Aging, 🫘 Kidney, ⚡ Energy & Fatigue. The primary research focus is 🔬 Oncology with 86% of studies addressing this area.
The following compounds share molecular targets with Sorafenib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Sorafenib is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.